

STN	Zdravotnícke pomôcky využívajúce živočíšne tkanivá a ich deriváty Časť 2: Kontroly pôvodu, odberu a manipulácie (ISO 22442-2: 2020)	STN EN ISO 22442-2
		85 6570

Medical devices utilizing animal tissues and their derivatives - Part 2: Controls on sourcing, collection and handling (ISO 22442-2:2020)

Táto norma obsahuje anglickú verziu európskej normy.
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 05/21

Obsahuje: EN ISO 22442-2:2020, ISO 22442-2:2020

Oznámením tejto normy sa ruší
STN EN ISO 22442-2 (85 6570) z apríla 2016

132838

EUROPEAN STANDARD

EN ISO 22442-2

NORME EUROPÉENNE

EUROPÄISCHE NORM

December 2020

ICS 11.100.20

Supersedes EN ISO 22442-2:2015

English Version

Medical devices utilizing animal tissues and their derivatives - Part 2: Controls on sourcing, collection and handling (ISO 22442-2:2020)

Dispositifs médicaux utilisant des tissus animaux et leurs dérivés - Partie 2: Contrôles de l'origine, de la collecte et du traitement (ISO 22442-2:2020)

Tierische Gewebe und deren Derivate, die zur Herstellung von Medizinprodukten eingesetzt werden - Teil 2: Kontrollen der Beschaffung, Materialgewinnung und Handhabung (ISO 22442-2:2020)

This European Standard was approved by CEN on 2 December 2020.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels

EN ISO 22442-2:2020 (E)

Contents	Page
European foreword.....	3
Annex ZA (informative) Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC as amended by Commission Regulation (EU) No 722/2012.....	5

European foreword

This document (EN ISO 22442-2:2020) has been prepared by Technical Committee ISO/TC 194 "Biological and clinical evaluation of medical devices" in collaboration with Technical Committee CEN/TC 206 "Biological and clinical evaluation of medical devices" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by June 2021, and conflicting national standards shall be withdrawn at the latest by June 2021.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 22442-2:2015.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For the relationship with EU Directive(s) see informative Annex ZA, which is an integral part of this document.

The following referenced documents are indispensable for the application of this document. For undated references, the latest edition of the referenced document (including any amendments) applies. For dated references, only the edition cited applies. However, for any use of this standard "within the meaning of Annex ZA", the user should always check that any referenced document has not been superseded and that its relevant contents can still be considered the generally acknowledged state-of-art.

When an IEC or ISO standard is referred to in the ISO standard text, this shall be understood as a normative reference to the corresponding EN standard, if available, and otherwise to the dated version of the ISO or IEC standard, as listed below.

NOTE The way in which these references documents are cited in normative requirements determines the extent (in whole or in part) to which they apply.

Table — Correlations between normative references and dated EN and ISO standards

Normative references as listed in Clause 2 of the ISO standard	Equivalent dated standard	
	EN	ISO or IEC
ISO 22442-1	EN ISO 22442-1:2020	ISO 22442-1:2020

EN ISO 22442-2:2020 (E)

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 22442-2:2020 has been approved by CEN as EN ISO 22442-2:2020 without any modification.

Annex ZA (informative)

Relationship between this European Standard and the Essential Requirements of EU Directive 93/42/EEC as amended by Commission Regulation (EU) No 722/2012

This European Standard has been prepared under a Commission's standardization request [M/023 concerning the development of European Standards related to medical devices] to provide one voluntary means of conforming to essential requirements of Council Directive 93/42/EEC of 14 June 1993 concerning medical devices [O] L 169].

Once this standard is cited in the Official Journal of the European Union under that Directive, compliance with the normative clauses of this standard given in Table ZA confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding essential requirements of that Directive and associated EFTA regulations.

NOTE 1 Where a reference from a clause of this standard to the risk management process is made, the risk management process needs to be in compliance with Directive 93/42/EEC as amended by 2007/47/EC. This means that risks have to be reduced 'as far as possible', 'to a minimum', 'to the lowest possible level', 'minimized' or 'removed', according to the wording of the corresponding essential requirement.

NOTE 2 The manufacturer's policy for determining acceptable risk must be in compliance with Essential Requirements 1, 2, 5, 6, 7, 8, 9, 11 and 12 of the Directive.

NOTE 3 This Annex ZA is based on normative references according to the table of references in the European foreword, replacing the references in the core text.

NOTE 4 When an Essential Requirement does not appear in Table ZA, it means that it is not addressed by this European Standard.

Table ZA.1 — Correspondence between this International Standard and Directive 93/42/EEC as amended by Commission Regulation (EU) No 722/2012

Essential Requirements of Directive 93/42/EEC	Clause(s)/sub-clause(s) of this EN	Remarks/Notes
7.1 first indent only	4 ,5, 6, 7, 8 and Annex A	Covered for the sourcing, collection and handling of materials of animal origin chosen for the manufacture of medical devices. Not covered for flammability. Not covered for manufacture.
7.2 first sentence only	4 ,5, 6, 7, 8 and Annex A	Covered for reducing risks to patients resulting from contaminants as far as the sourcing, collection and handling of materials used in medical devices based on animal tissues and their derivatives is concerned, providing any resulting risks are minimized. Not covered for packing, manufacture, transport or storage.

EN ISO 22442-2:2020 (E)

Essential Requirements of Directive 93/42/EEC	Clause(s)/sub-clause(s) of this EN	Remarks/Notes
8.1 first sentence only	4 ,5, 6, 7, 8 and Annex A	Covered for reducing risks of infection to patients as far as the sourcing, collection and handling of materials used in medical devices based on animal tissues and their derivatives is concerned, providing any resulting risks are eliminated or reduced as far as possible. Not covered for manufacture.
8.2 first paragraph of third paragraph only	4 ,5, 6, 7, 8 and Annex A	Covered for the handling of materials used in medical devices based on animal tissues and their derivatives
Annex I of Commission Regulation (EU) No 722/2012	4 ,5, 6, 7, 8 and Annex A	The requirements detailed in Section 1 of Annex I of Reg. 722/2012/EC cover risk analysis and risk management of medical devices manufactured utilising non-viable tissues, or derivatives thereof, sourced from animals that are susceptible to TSEs, as defined in Art. 1.2. The Regulation is therefore specific to TSE risks. Annex I of the Regulation requires implementation of risk control measures, including controls on sourcing, collection and handling of animal-derived material, to manage TSE risks.

WARNING 1 — Presumption of conformity stays valid only as long as a reference to this European Standard is maintained in the list published in the Official Journal of the European Union. Users of this standard should consult frequently the latest list published in the Official Journal of the European Union.

WARNING 2 — Other Union legislation may be applicable to the products falling within the scope of this standard.

**INTERNATIONAL
STANDARD**

**ISO
22442-2**

Third edition
2020-09

**Medical devices utilizing animal
tissues and their derivatives —**

Part 2:
**Controls on sourcing, collection and
handling**

*Dispositifs médicaux utilisant des tissus animaux et leurs dérivés —
Partie 2: Contrôles de l'origine, de la collecte et du traitement*



Reference number
ISO 22442-2:2020(E)

© ISO 2020

ISO 22442-2:2020(E)**COPYRIGHT PROTECTED DOCUMENT**

© ISO 2020

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword	iv
Introduction	v
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 General requirements	2
4.1 General.....	2
4.2 Quality system elements.....	2
4.3 Procedures.....	3
4.4 Personnel.....	3
4.5 Current regulatory requirements and guidance.....	4
5 Sourcing	4
5.1 General.....	4
5.2 Species and strain.....	4
5.3 Geography.....	4
5.4 Inspection.....	4
5.5 Certification.....	5
5.6 Traceability.....	5
6 Collection	5
7 Handling	6
8 Storage, transport and labelling	6
Annex A (normative) Additional requirements relating to the application of this document to bovine-sourced materials and other TSE relevant animal species	7
Annex B (informative) Certification and attestation	13
Bibliography	15

ISO 22442-2:2020(E)

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*, Subcommittee SC 1, *Tissue product safety*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, *Biological and clinical evaluation of medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This third edition cancels and replaces the second edition (ISO 22442-2:2015).

The main changes compared to the previous version are as follows:

- update of the weblink on stunning technique in [A.3.2.5](#) Note 1;
- clarification on scope inclusion of cervid-sourced materials, and other TSE susceptible species;
- clarification on atypical BSE types, especially in combination with intracranial applications;
- enhanced expectation of using validated biochemical testing to establish TSE presence.

A list of all parts in the ISO 22442 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

Certain medical devices utilize materials of animal origin.

Animal tissues and their derivatives are used in the design and manufacture of medical devices to provide performance characteristics that have been chosen for advantages over non-animal based materials. The range and quantities of materials of animal origin in medical devices vary. These materials can comprise a major part of the device (e.g. bovine/porcine heart valves, bone substitutes for use in dental or orthopaedic applications, haemostatic devices), can be a product coating or impregnation (e.g. collagen, gelatine, heparin), or can be used in the device manufacturing process (e.g. tallow derivatives such as oleates and stearates, foetal calf serum, enzymes, culture media).

Tissues and derivatives for use in medical devices are typically obtained by the manufacturer from a range of sources such as animal herds or flocks and commercial harvesting (including fishing). Some specialized industries also process materials of animal origin to manufacture a finished product (e.g. gelatine) which is incorporated as a raw material into the finished medical device by the manufacturer.

This document is intended to be used in conjunction with the other two parts of the ISO 22442 series. Local safety regulations can apply. The manufacturers should refer to ISO 22442-3 for information on the validation of the elimination and/or inactivation of viruses and TSE agents.

It is not a requirement of this document to have a full quality management system during manufacture, but it does specify requirements for some of the elements of a quality management system. Attention is drawn to the standards for quality management systems (see ISO 13485) that control all stages of production or reprocessing of medical devices. The quality management system elements that are required by this document can form a part of a quality management system conforming to ISO 13485.

Medical devices utilizing animal tissues and their derivatives —

Part 2: Controls on sourcing, collection and handling

1 Scope

This document specifies requirements for controls on the sourcing, collection, and handling (which includes storage and transport) of animals and tissues for the manufacture of medical devices utilizing materials of animal origin other than *in vitro* diagnostic medical devices. It applies where required by the risk management process as described in ISO 22442-1.

NOTE Selective sourcing is especially important for transmissible spongiform encephalopathy (TSE) risk management, i.e. when utilising animal tissue and/or their derivative originating from bovine, ovine and caprine species, deer, elk, mink or cats.

This document does not cover the utilization of human tissues in medical devices.

This document does not specify a quality management system for the control of all stages of production of medical devices.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 22442-1, *Medical devices utilizing animal tissues and their derivatives — Part 1: Application of risk management*

koniec náhľadu – text ďalej pokračuje v platenej verzii STN